GlobeNewsWire
21 Jul 2026, 16:50 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
AstraZeneca's late-stage Phase-3 CARDIO-TTransform trial for the amyloid cardiomyopathy treatment Wainua failed to meet its primary endpoint. — Failure of a late-stage clinical trial for a key pipeline drug directly reduces the company's future revenue potential and valuation.
-0.60Pomerantz LLP is investigating AstraZeneca for potential securities fraud or unlawful business practices following the trial failure. — Legal investigations and potential class-action lawsuits create additional regulatory risk and potential financial liabilities.
-0.30Which stocks this story touches
Facing a class action investigation following a failed Phase-3 clinical trial and a significant drop in share price.
Continue reading
6 related stories
Top 1 mover · tap to explore
Subject of a legal investigation into claims on behalf of investors.
Subject of a legal investigation into claims on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
